Impact of Advanced Therapy Medicinal Products status in European regulations on their production cost: The case of hematopoietic stem cells

Impact du statut des médicaments de thérapie innovante dans la réglementation européenne sur leur coût de production: le cas des cellules souches hématopoïétiques

Thibault Cousin, Frederic Chantreuil (), Eric Barat (), Olivier Boyer, Francoise Norol (), Rémi Varin (), Isabelle Lebon and Camille Giverne
Additional contact information
Thibault Cousin: CLCC Henri Becquerel - Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen
Frederic Chantreuil: UNC - Université de la Nouvelle-Calédonie, LARJE - Laboratoire de Recherches Juridique et Economique - UNC - Université de la Nouvelle-Calédonie
Eric Barat: CHU Rouen - NU - Normandie Université
Olivier Boyer: PANTHER - Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices - UNIROUEN - Université de Rouen Normandie - NU - Normandie Université - INSERM - Institut National de la Santé et de la Recherche Médicale, CHU Rouen - NU - Normandie Université
Francoise Norol: CHU Pitié-Salpêtrière [AP-HP] - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - SU - Sorbonne Université
Rémi Varin: CHU Rouen - NU - Normandie Université
Camille Giverne: PANTHER - Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices - UNIROUEN - Université de Rouen Normandie - NU - Normandie Université - INSERM - Institut National de la Santé et de la Recherche Médicale, CHU Rouen - NU - Normandie Université

Post-Print from HAL

Abstract: Objectives: The therapeutic promises of somatic cell and gene therapy (Advanced Therapy Medicinal Products - ATMP) and the significant current or future costs of such therapies raise questions about the impact of European health policy on these expenses. Regulation 1394/2007 currently imposes the medicinal product status on many treatments derived from cell therapy. This study aims to determine the impact of new regulations on manufacturing costs of cell therapy treatments, used as ATMP. Methods: In our study, using counterfactual reasoning, we analyze the consequences that a change of status would have on the hematopoietic stem cells (HSC) used for treatment of leukemia. Results: Under the existing status of cell transplantation (CT, Directive 2004/23/EC), the annual production cost of these cell therapy products (CTP) in France is estimated at euro 5.6 million. If the HSC used in leukemia indication were under the medicinal product status of ATMP, the cost would rise to approximately euro 9.9 million, without accounting for expenses related to facilities, which are much higher for ATMP than for CT. Conclusion: This additional burden for manufacturers must be weighed against the theoretical benefits for patients, such as reduced contamination risk. Given the very low contamination levels reported by facilities using transplant standards, the extra cost seems excessive and could hinder the development of new advanced therapies. Furthermore, it raises the need to adapt existing Good Manufacturing Practice guidelines for autologous products or those made from a single donor for a single patient, ensuring safety and cost reduction, which should encourage further development of cell therapy.

Keywords: Advanced Therapy Medicinal Products; Cell Transplantation; Cost; Regulation; Security; Coût; Médicaments de Thérapie Innovante; Réglementation; Sécurité; Transplantation Cellulaire (search for similar items in EconPapers)
Date: 2025
Note: View the original document on HAL open archive server: https://hal.science/hal-04927306v1
References: Add references at CitEc
Citations:

Published in Annales Pharmaceutiques Françaises, 2025, ⟨10.1016/j.pharma.2025.01.013⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-04927306

DOI: 10.1016/j.pharma.2025.01.013

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().